ESC 2025 29 August - 1 September 2025

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

Authors :

Lauren Wilson1; Zhenxiang Zhao1; Victoria Divino1; Matthew Bassan1; Briain O Hartaigh1; Kerem Ozer1

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
Obesity
Congress oral presentation
GLP-1 RA
Semaglutide
RWE HEOR